› Forums › General Melanoma Community › that time again in australia
- This topic is empty.
- Post
-
- February 7, 2013 at 8:28 pm
Hi again from Australia. Our government is asking again for information to help them decide on drug costs reimbursment to patients. And again i would like anyone who has any knowledge of the drug and treatment to click on the link and add their thoughts. the link is only open until 13.02.13.
No changes here for my daughter… still cannot get any doctor or specialist to see her…We get the same response everywhere…(she has a specialist so we cannot see her. The problem is she does not have any private insurance so is at the bottom of the list).
Hi again from Australia. Our government is asking again for information to help them decide on drug costs reimbursment to patients. And again i would like anyone who has any knowledge of the drug and treatment to click on the link and add their thoughts. the link is only open until 13.02.13.
No changes here for my daughter… still cannot get any doctor or specialist to see her…We get the same response everywhere…(she has a specialist so we cannot see her. The problem is she does not have any private insurance so is at the bottom of the list).
Her specialist (allocated by the hospital) is a surgeon and while he is excellent at his job , his attitude is , "if you find a tumor , i will cut it out"". I am still searching for a specialist that will help her monitor her body , the surgeon does not do this. Her local GP is doing a very good job of monioring her general health at the moment and we are relying on this at the moment…the search goes on…
PS, she can book into a dermatoligist however in Australia the waiting list is over 1 and half years… She is on lists..
again…if you get melanoma…dont get it in austalia…..
very kind regards from Bron (Australia).
PBAC Invites Consumer Comment on Zelboraf Reimbursement
Zelboraf (vemurafenib) (commonly known amongst melanoma patients as BRAF therapy) was first considered by the Pharmaceutical Benefits Advisory Committee (PBAC) in July 2012, where a decision on recommending the medicine for PBS listing was deferred to allow the PBAC to obtain further information. The PBAC will again consider Zelboraf in March 2013.
The PBAC welcomes members of the general public to make comment on the application for a specific medicine being considered for PBS listing. The PBAC accepts these submissions, called Consumer Comments, from patients, carers, members of the public, healthcare professionals or members of consumer interest groups.
Consumer Comments in relation to Zelboraf, or any other medicine being considered by the PBAC in March 2013, close on 13 February 2013. Information on making a Consumer Comment is available at: http://tinyurl.com/b48nexn
If you would like to make a comment the PBAC provides some questions to guide your comments (please see below). You do not have to answer all the questions. Information should be included that would help the PBAC understand how this health problem or disease affects Australians, and their families and carers.
1. What treatment (if any) are you using now?
Please describe what medicines you take to treat your health problem and how well this treatment works.
2. What do you see as the benefits of this new medicine for you?
Please describe the benefits you think the new medicine could have for your health? Do you think the new medicine could have any disadvantages?
3. How will your life and that of your family and carers be improved by this new medicine?
Please describe how you think this medicine will affect your life and the lives of your family or carers. Please explain why you think this.
4. What other benefits can you see from having this medicine on the PBS?
Please describe any other benefits you think will come from having this medicine listed on the PBS (for example: fewer hospital visits, reduced time off work and so on).
5. Do you have any comments on the consumer input process?
Please provide comments or suggestions on how this process could be improved (are the questions appropriate?, what worked well?, what needs improvement?).
Consumer Comments can be submitted in the following ways:
Online: http://tinyurl.com/a569arg
Email: [email protected]
Mail: PBAC Secretariat
MDP 952, Department of Health and Ageing
GPO Box 9848
Canberra, ACT, 2601
Fax: 02-6289 4175
- You must be logged in to reply to this topic.